1 Edwards JE Jr,Bodey GP,Bowden RA,et al.International conference for the development of a consensus on the management and prevention of severe candidal infections.Clin Infect Dis.1997.25:43-59. 2 Chaisson RE,Gallant JE,Keruly JC,et al.Impact of opportunistic disease on survival in patients with HIV infection.AIDS,1998.12:29-33. 3 Schuetzer-Muehlbauer M,Willinger B,Egner R,et al.Reversal of antifungal resistance mediated by ABC efflux pumps from Candida albicans functionally expressed in yeast.lnt J Antimicrob Agents,2003.22:291-300 4 Marchetti O,Moreillon P,Glauser MP,et al.Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans.Antimicrob Agents Chemother.2000,44:2373-2381. 5 许文林,江云伟,工法春,等.汉防己甲素逆转白血病细胞株K562/ADM多药耐药性机制研究.实用癌症杂志,2003.18:347-349. 6 Fu LW,Zhang YM,Liang YJ,et al.The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenografts derived from human breast adenocarcinoma MCF-7/adr cells.Eur J Cancer,2002.38:418-426. 7 van Veen HW,Konings WN.Multidrug transporters from bacteria to man:similarities in structure and function.Semin Cancer Biol.1997.8:183-191. 8 White TC.Pfaller MA,Rinaldi MG,et al.Stable azole drug resis-Lance associated with a substrain of Candida albicans from an HIV-infected patient.Oral Dis.1997.3:S102-5109. 9 National Committee for Clinical Laboratory Standards.Reference method for broth dilution antifimgal susceptibility testing of yeasts:approved standard [S].NCCLS document M27-A.Wayne,Pennsylvania:NCCLS.1997. 10 White TC.Increased mRNA levels of ERG16.CDR,and MDRI correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus.Antimicrob Agents Chemother,1997,41:1482-1487. 11 Sanglard D,lscher F,Monod M,et al.Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors.Antimicrob Agents Chemother.1996,40:2300-2305. 12 罗明生.现代临床药物大典.成都:四川科学技术出版社,2001.388-389. |